Use of Individualized Homoeopathic medicines and Glycyrrhiza glabra mother tincture in the treatment of Hyperlipidemia

Not yet recruiting

• Conditions: Hyperlipidemia, unspecified,

• Registration Number: CTRI/2022/07/043957
• Lead Sponsor: National Institute of Homoeopathy

Brief Summary

Hyperlipidemia is considered as one of the major risk factors causing cardiovascular diseases (CVDs). It is commonly seen in above the age of 25 years. Researches showed that overall, 33.8% of the population presented any of the forms of hyperlipidemia, being more frequent in men (50.6%) than in women (28.8%). It causes Tuberous xanthomas in the Achilles tendon, hands, feet, elbows, and/or knees and Corneal arcus of the eye, Dyspnea, Paresthesia and Confusion. It does not have symptoms at all, but it can cause other symptomatic vascular disease, like coronary artery disease. Proper case taking is done and patients will be divided into two parallel arms. 50% patients will receive individualized homoeopathic medicines and 50% will receive Glycyrrhiza glabra mother tincture. Each enrolled case will be followed up monthly, Serum lipid profile will be done at the baseline, 3rd month, and at 6thmonth to assess/compare the change in serum lipid level. The assessment of the outcome of the treatment will be done using COOP/WONCA Functional Assessment chart gradation at the baseline, 3rd month, and at 6th month in particular level.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-13
• Last Update Posted: 2022-12-07

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• a) Patients of both sexes and all religions.
• b)Patients with Body Mass Index (BMI): For females 25–30 and For males 26–30.
• c) Patients already undergoing to regular therapy for hyperlipidemia, provided the medication are stopped completely at least 2 weeks prior study entry.
• d) Patients giving written consent to participate in the study.

Exclusion Criteria

• a) Patients of age group below 30 and above 70 years.
• b) Patients with BMI: Females, BMI < 19, Males, BMI < 20 c) Patients who will be too sick for consultation.
• d) Patients of diagnosed cases of systemic diseases, unstable mental or psychiatric illness or other uncontrolled or life threatening illness affecting quality of life or any organ failure, pregnancy and lactation, substance abuse and/or dependence, self reported immunocompromised state, and patients availing homeopathic treatment for chronic disease within last 6 months.
• e) Patients unwilling to take part or not giving consent to participate in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It will be done using Serum lipid profile according to NCEP desirable cholesterol level as:	At the baseline, 3rd month, and at 6th month
Total Cholesterol - 200mg/dl.	At the baseline, 3rd month, and at 6th month
LDL Cholesterol - 130 mg/dl.	At the baseline, 3rd month, and at 6th month
HDL Cholesterol - 50 mg/dl.	At the baseline, 3rd month, and at 6th month
Triglycerides - 200 mg/dl.	At the baseline, 3rd month, and at 6th month

Secondary Outcome Measures

Name	Time	Method
It will be done by assessing quality of life of patients on the basis of score obtained from COOP/WONCA Functional Assessment Chart. It measures six core aspects of functional status:	Physical fitness, Feelings, Daily activities, Social activities, Change in health and Overall health.

Trial Locations

Locations (1)

National Institute of Homoeopathy; 🇮🇳 Kolkata, WEST BENGAL, India

National Institute of Homoeopathy

🇮🇳Kolkata, WEST BENGAL, India

Dr Akanksha Kumari

Principal investigator

8294729274

kumariakanksha15495@gmail.com